Abstract
The in vitro activity of fusidic acid was assessed and was compared with those of cloxacillin, cefamandole, vancomycin, teicoplanin, ofloxacin, ciprofloxacin, pefloxacin, and fleroxacin against 500 gram-positive cocci: 151 Staphylococcus aureus, 197 coagulase-negative staphylococci, and 152 Enterococcus faecalis strains. All clinical isolates were concomitantly tested by disk diffusion and agar dilution procedures as outlined by the National Committee for Clinical Laboratory Standards. The results with fusidic acid were further analyzed by regression line and error rate-bounded methods. With control American Type Culture Collection organisms, the values were within the limits of the National Committee for Clinical Laboratory Standards or published limits. The incidence of resistance to fusidic acid was 0.7% for S. aureus, 2.5% for coagulase-negative staphylococci, and 99.3% for E. faecalis. The correlation coefficient between the results of disk diffusion and agar dilution tests with fusidic acid was 0.90. Current interpretive criteria for susceptibility to fusidic acid (i.e., MIC of < 2 micrograms/ml and inhibitory zone of 20 mm) gave 1% false susceptibility (all strains being E. faecalis). This error rate is practically eliminated if a zone diameter of 21 mm is considered the breakpoint for susceptibility.
Full Text
The Full Text of this article is available as a PDF (191.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Archer G. L., Climo M. W. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother. 1994 Oct;38(10):2231–2237. doi: 10.1128/aac.38.10.2231. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Barry A. L., Jones R. N. In vitro activity of ciprofloxacin against gram-positive cocci. Am J Med. 1987 Apr 27;82(4A):27–32. [PubMed] [Google Scholar]
- Faber M., Rosdahl V. T. Susceptibility to fusidic acid among Danish Staphylococcus aureus strains and fusidic acid consumption. J Antimicrob Chemother. 1990 Feb;25 (Suppl B):7–14. doi: 10.1093/jac/25.suppl_b.7. [DOI] [PubMed] [Google Scholar]
- GODTFREDSEN W., ROHOLT K., TYBRING L. Fucidin: a new orally active antibiotic. Lancet. 1962 May 5;1(7236):928–931. doi: 10.1016/s0140-6736(62)91968-2. [DOI] [PubMed] [Google Scholar]
- Guenthner S. H., Wenzel R. P. In vitro activities of teichomycin, fusidic acid, flucloxacillin, fosfomycin, and vancomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1984 Aug;26(2):268–269. doi: 10.1128/aac.26.2.268. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones R. N., Barry A. L. Antimicrobial activity of coumermycin and recommendations for disk diffusion tests with 5- and 15-micrograms disks. Diagn Microbiol Infect Dis. 1987 May;7(1):77–82. doi: 10.1016/0732-8893(87)90075-7. [DOI] [PubMed] [Google Scholar]
- MacGowan A. P., Greig M. A., Andrews J. M., Reeves D. S., Wise R. Pharmacokinetics and tolerance of a new film-coated tablet of sodium fusidate administered as a single oral dose to healthy volunteers. J Antimicrob Chemother. 1989 Mar;23(3):409–415. doi: 10.1093/jac/23.3.409. [DOI] [PubMed] [Google Scholar]
- Metzler C. M., DeHaan R. M. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J Infect Dis. 1974 Dec;130(6):588–594. doi: 10.1093/infdis/130.6.588. [DOI] [PubMed] [Google Scholar]
- Pohlod D. J., Saravolatz L. D., Somerville M. M. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin. J Antimicrob Chemother. 1987 Aug;20(2):197–202. doi: 10.1093/jac/20.2.197. [DOI] [PubMed] [Google Scholar]
- Reeves D. S. The pharmacokinetics of fusidic acid. J Antimicrob Chemother. 1987 Oct;20(4):467–476. doi: 10.1093/jac/20.4.467. [DOI] [PubMed] [Google Scholar]
- Taburet A. M., Guibert J., Kitzis M. D., Sorensen H., Acar J. F., Singlas E. Pharmacokinetics of sodium fusidate after single and repeated infusions and oral administration of a new formulation. J Antimicrob Chemother. 1990 Feb;25 (Suppl B):23–31. doi: 10.1093/jac/25.suppl_b.23. [DOI] [PubMed] [Google Scholar]
- Traub W. H., Kleber I. Interpretation of diffusion susceptibility data obtained with 10-mug fucidin (sodium fusidate) disks against clinical isolates of Staphylococcus aureus. Chemotherapy. 1974;20(2):92–96. doi: 10.1159/000221796. [DOI] [PubMed] [Google Scholar]
- Verbist L. The antimicrobial activity of fusidic acid. J Antimicrob Chemother. 1990 Feb;25 (Suppl B):1–5. doi: 10.1093/jac/25.suppl_b.1. [DOI] [PubMed] [Google Scholar]
- Wise R., Pippard M., Mitchard M. The disposition of sodium fusidate in man. Br J Clin Pharmacol. 1977 Oct;4(5):615–619. doi: 10.1111/j.1365-2125.1977.tb00795.x. [DOI] [PMC free article] [PubMed] [Google Scholar]